The healthcare scene is home to some pretty defensive companies that aren’t exactly shying away from medical innovation. With the following Strong-…

DXCM earnings call for the period ending March 31, 2024.

DexCom (NASDAQ: DXCM ) just reported results for the first quarter of 2024. DexCom reported earnings per share of 32 cents. This was above the analyst estimate for EPS of 27 cents. The company reported revenue of $921.00 million. This was 1.29% better than the analyst estimate for revenue of $909.24 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.

No summary available.

Dexcom''s Q1 2024 results exceed expectations, but the stock is down in after-hours trading. Read more here.

The following slide deck was published by DexCom, Inc.

DexCom (NASDAQ: DXCM ) has outperformed the market over the past 5 years by 23.93% on an annualized basis producing an average annual return of 35.38%. Currently, DexCom has a market capitalization of $51.74 billion. Buying $1000 In DXCM: If an … Full story available on Benzinga.com

People are interested in ETFs for weight loss because of Oprah’s TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she’s talking to patients and doctors about using prescription drugs to lose weight, but it’s still causing a stir. It’s also big news that Oprah is leaving the Weight Watchers board . The fact that she backs drugs like Mounjaro, Wegovy and Ozempic shows how times are changing for everyone. It’s always been hard for the famous talk show host to lose weight. But because she was so famous, everything she suggested to lose weight sold out very quickly. In other words, we see the same pattern with drugs that help people lose weight. Because of Oprah’s ABC special , the dieting business and the practice of dieting are changing. This is like what happened when she really tried to lose weight in 1998. The only difference is the methodology she’s adopting. But be careful while Oprah fights the social shame that comes with losing weight with Ozempic.